Description of service

This TNA is for production of GMP compliant starting material. The VVCF will produce Adenovirus and/or MVA vector(s) expressing antigen(s) of interest to the accessor, with appropriate QC. Vector design, for example insert size, expression of multiple antigens, inclusion of a signal sequence and Adenovirus backbone, will be discussed. When required, both Ad and MVA vectors expressing the same antigen(s) can be produced, to enable prime-boost vaccination strategies. Several different Ad backbones are available (human/primate).


1 viral vectored vaccine (GMP compliant), either Adenovirus or MVA.


Dr. Claire Powers, VVCF Manager

0044 (0)1865 287761

Services do NOT include

Additional QC e.g. sequencing and mycoplasma. Preparation of GMP starting material (to be discussed with user).

Possible Output

To be discussed with user: For MVA, markerless virus potentially suitable for transfer to GMP manufacturing organisation (frozen in aliquots, with QC data: titre in pfu, sterility and identity/purity assessed by PCR). For Ad, virus or DNA (whole genome plasmid) which could be used to prepare pre-GMP starting material.

Sample Requirements - input of users

DNA encoding the antigen(s), and DNA sequence data. Function of the antigen and potential pathogenicity. Prior experience expressing antigen, e.g. relevant publications. Any other relevant information e.g. expressed as trimer, is secreted/has transmembrane domain, is glycosylated.

Lead Scientist

Professor Adrian Hill

Production of GMP compliant Adenovirus and/or MVA vector(s) expressing antigen(s) of interest


VVCF also produces recombinant viral vectors  for pre-clinical vaccine studies and other purposes for external academic and industrial collaborators. More information on additional services for vector production here

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon
Subscribe to TRANSVAC´s Mailing list

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative